Aplastic Crisis
A rapid, severe drop in hemoglobin with absent reticulocytes in a patient with chronic hemolytic anemia, typically due to Parvovirus B19 infection.
Emergency Management: Cardiovascular collapse or high-output heart failure requiring emergent cross-matched pRBC transfusion and hemodynamic support.
Aplastic crisis is a transient, life-threatening cessation of red blood cell production in the bone marrow, primarily occurring in patients with chronic hemolytic anemias such as sickle cell disease or hereditary spherocytosis. It is classically triggered by Parvovirus B19 infection, which directly infects and destroys erythroid progenitor cells. The resulting severe anemia develops rapidly due to the already shortened lifespan of red blood cells in these underlying conditions.
Detailed Overview
The hallmark of an aplastic crisis is a precipitous drop in hemoglobin levels coupled with an inappropriately low reticulocyte count (often <1%). Parvovirus B19 targets the P antigen (globoside) on the surface of erythroid progenitors. While a normal host can tolerate a 10-14 day halt in erythropoiesis because normal RBCs live 120 days, patients with hemolytic anemias whose RBCs live only 10-20 days experience severe, symptomatic anemia. It is self-limiting but requires prompt recognition and supportive transfusion to prevent cardiovascular collapse.
Epidemiology & Demographics
Most common in children and adolescents with sickle cell disease (HbSS) or hereditary spherocytosis. Approximately 70% of sickle cell patients experience Parvovirus B19 infection by age 20. Epidemics often occur in late winter or early spring.
Etiological Mechanism
Infection with Parvovirus B19, a single-stranded DNA virus. Other rare viral triggers include Epstein-Barr virus (EBV), cytomegalovirus (CMV), and HIV.
Primary Causes
Primary cause is Parvovirus B19 infection occurring in a host with baseline chronic hemolysis (e.g., Sickle Cell Anemia, Thalassemia major, Hereditary Spherocytosis, Pyruvate Kinase deficiency).
Parvovirus B19 binds to the blood group P antigen on erythroid colony-forming units (CFU-E) and proerythroblasts. The virus enters the cell, replicates in the nucleus, and induces cellular apoptosis. This causes a complete cessation of erythropoiesis for 7 to 10 days. In normal individuals, this causes a mild, unnoticeable drop in hemoglobin. In patients with baseline hemolytic anemia (RBC half-life <20 days), the complete lack of RBC replacement leads to an acute, severe drop in hemoglobin, often falling by 2 g/dL per day.
Diagnostic Criteria & Guidelines
Diagnosed by a rapid drop in hemoglobin (often >2 g/dL below baseline) accompanied by profound reticulocytopenia (absolute reticulocyte count <10,000/microL or <1%) in a patient with known chronic hemolytic anemia, with positive Parvovirus B19 IgM or PCR.
Supportive care is paramount. Packed Red Blood Cell (pRBC) transfusions are the primary treatment. Administer pRBCs (10-15 mL/kg in pediatrics or 1-2 units in adults) to maintain hemoglobin at a safe level (typically >7 g/dL) until spontaneous bone marrow recovery occurs. Strict droplet isolation precautions in the hospital setting to prevent transmission to pregnant women or immunocompromised patients.
Second-Line & Adjunctive Therapy
IVIG (Intravenous Immunoglobulin) 400 mg/kg/day for 5 days is typically reserved for immunocompromised patients who are unable to clear the parvovirus infection and develop chronic pure red cell aplasia, not standard aplastic crisis.
Surgical & Procedural Management
None indicated for acute aplastic crisis.
Patient Counseling & Advice
Reassure patients that infection with Parvovirus B19 confers lifelong immunity; therefore, typical aplastic crisis from this virus is an isolated, once-in-a-lifetime event. Stress the importance of immediate medical evaluation for symptoms of severe fatigue or pallor.
Follow-Up & Monitoring Schedule
Weekly CBC and reticulocyte counts until full marrow recovery and return to baseline hemoglobin. Monitor iron stores if multiple transfusions were required.
Preventive Strategies
Hand hygiene and infection control. No vaccine currently exists for Parvovirus B19. Pregnant healthcare workers should avoid caring for these patients due to the risk of fetal hydrops.
Excellent with prompt transfusion support. The bone marrow typically recovers spontaneously within 7-14 days. Without treatment, it can be fatal due to anemic shock.